Guardant Health Inc. (GH)
NASDAQ
Closed
Aug 25, 2026
Day's Range
161.8252 wk Range
53.40Overview - GH - Guardant Health Inc.
Key Statistics
Valuation
Enterprise Value
23.54B
P/E (Trailing)
‪-49.15‬
P/E (Forward)
‪-379.20‬
PEG Ratio
‪-3.93‬
Price / Sales (TTM)
‪19.36‬
Price / Book
‪-97.28‬
EV / EBITDA
‪-54.69‬
Profitability
Gross Margin
‪65.38%‬
Profit Margin
‪-38.32%‬
Operating Margin
‪-38.24%‬
Return on Assets
‪-18.07%‬
Return on Equity
‪419.18%‬
Ownership
Shares Outstanding
133.61M
Float
129.39M
Short % of Shares Outstanding
‪8.87%‬
Held by Insiders
‪3.97%‬
Held by Institutions
‪100.91%‬
Price stats
Beta
‪1.58‬
50-Day Avg
‪153.16‬
200-Day Avg
‪114.02‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
25 analysts
Average price target
‪$ 194.29‬Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - GH - Guardant Health Inc.
Peers - GH - Guardant Health Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on NASDAQ.
- GHNASDAQGuardant Health Inc.21.89BMarket Cap+62.08%52-week change-49.15P/E (Trailing)‪-38.32%‬Profit Margin
- NTRANASDAQNATERA INC (Common Stock) – ticker 45E47.86BMarket Cap+50.33%52-week change-215.11P/E (Trailing)‪-7.10%‬Profit Margin
- IDXXNASDAQIDEXX Laboratories, Inc.44.07BMarket Cap-14.69%52-week change39.06P/E (Trailing)‪25.03%‬Profit Margin
- ILMNNASDAQIllumina, Inc.33.70BMarket Cap+55.77%52-week change41.01P/E (Trailing)‪18.33%‬Profit Margin
- MEDPNASDAQMedpace Holdings Inc.17.30BMarket Cap+24.71%52-week change36.41P/E (Trailing)‪17.66%‬Profit Margin
- ICICLRNASDAQICON plc13.38BMarket Cap-0.84%52-week change264.97P/E (Trailing)‪0.32%‬Profit Margin
- RDNTNASDAQRadNet Inc.5.87BMarket Cap+6.83%52-week change1425.75P/E (Trailing)‪-0.93%‬Profit Margin
Profile Summary - GH - Guardant Health Inc.
About
Guardant Health Inc. is a precision oncology company that develops blood- and tissue-based tests to support cancer care across multiple stages of the disease. Its current portfolio includes genomic profiling for advanced cancer, minimal residual disease and recurrence monitoring, and screening focused on earlier…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
